"Rather than obsess about charts and the stock structure of Neurotrope would be critics should address the science of Synaptic Loss and its consequences and treatment"
Wolf, I think the problem is that because AD drugs have all failed in the past, the mindset for investors that chase AD bio stocks has been that they have to figure out how to make money from the failure. They are use to companies that drag studies on forever and only promise news in the future that never comes. So cut them some slack for being stuck in that rut. The best thing going here is that they have attacked severe cases in the 2b trial so results could be vary telling.
News 
Market Data 
Discover 
